MYFEMBREE: payments to doctors
Payments that named MYFEMBREE as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $4.8M
- Providers
- 26,207
- Transactions
- 156,873
- Average per transaction
- $31
The per-transaction average — $31 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 26,207 providers the average total is $185, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Sumitomo Pharma America, Inc. | $1,770,931 | 36.6% |
| Myovant Sciences Inc. | $1,590,053 | 32.9% |
| Pfizer | $1,455,988 | 30.1% |
| Whitehall International Inc | $16,000 | 0.3% |
| Myovant Sciences GmbH | $5,185 | 0.1% |
| PBG Puerto RICO LLC | $1,358 | 0.0% |
| Array Biopharma Inc | $45 | 0.0% |